Skip to main content
Premium Trial:

Request an Annual Quote

Selventa, Rosa Partner on Drug Discovery and Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Selventa today announced a scientific partnership with Rosa aimed at new drug discovery and development.

Financial and other terms of the deal were not disclosed.

In a statement, Cambridge, Mass.-based Selventa, formerly called Genstruct, said that the alliance provides "access to a synergistic combination of knowledge assets, proprietary data, physiologic model libraries, and expertise in disease areas such as oncology, immunology, respiratory, inflammatory, and metabolic diseases."

The two firms' combined modeling and analysis will integrate genomic, transcriptomic, in vitro, animal, and clinical data in a quantitative model.

Rosa provides drug-disease modeling and simulation services and has offices in Silicon Valley, Philadelphia, Seattle, and Europe.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.